Adagene Inc. (ADAG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Adagene Inc. (ADAG) closed at USD 2.29 on 2026-10-14, a change of +27.2 % over the past year, with a market capitalization of USD 161.14M.

Adagene Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Adagene Inc. key figures

Previous close

USD 2.29 (2026-10-14)

1-year change

+27.2 %

Market cap

USD 161.14M

Enterprise value

USD 55.88M

P/E ratio (trailing)

-6.67

P/E ratio (forward)

-4.29

EPS (trailing)

-0.36

EPS (forward)

-0.56

PEG ratio

n/a

Price to book

1.80

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.51

Employees

128

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Adagene Inc.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Adagene Inc. and compare it with other stocks.